{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:06:53Z","timestamp":1724976413109},"reference-count":20,"publisher":"ALUNA","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:p>Pityriasis Rubra Pilaris is a rare, chronic inflammatory dermatosis of unknown etiology, presenting with erythema and papular eruptions. Treatment is difficult due to the lack of causal therapy, guidelines and requires an individualized approach. The most common treatments are systemic retinoids, immunosuppressants, phototherapy and biological therapy. This article presents the case of a 73-year-old man suffering from type 1 pityriasis rubra pilaris. The patient was initially treated with acitretin, which was discontinued due to hypogammaglobulinemia. This rare side effect of acitretin has not been previously published. As a second-line treatment, the patient received methotrexate, but with no clinical improvement after 3 months and an increase in skin pruritus. Finally, the use of isotretinoin resulted in significant clinical improvement and was well tolerated.<\/jats:p>","DOI":"10.36740\/merkur202403114","type":"journal-article","created":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T11:58:20Z","timestamp":1721044700000},"page":"363-367","source":"Crossref","is-referenced-by-count":0,"title":["Pityriasis Rubra Pilaris \u2013 a difficult path to optimal treatment. Case report"],"prefix":"10.36740","volume":"52","author":[{"given":"Jakub","family":"Smyk","sequence":"first","affiliation":[{"name":"DEPARTMENT OF RHEUMATOLOGY AND IMMUNOLOGY, ANDRZEJ FRYCZ-MODRZEWSKI CRAKOW UNIVERSITY, CRAKOW, POLAND"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicja","family":"Kami\u0144ska","sequence":"additional","affiliation":[{"name":"DEPARTMENT OF RHEUMATOLOGY AND IMMUNOLOGY, ANDRZEJ FRYCZ-MODRZEWSKI CRAKOW UNIVERSITY, CRAKOW, POLAND"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Przemys\u0142aw","family":"Borowy","sequence":"additional","affiliation":[{"name":"DEPARTMENT OF RHEUMATOLOGY AND IMMUNOLOGY, J. DIETL HOSPITAL, CRACOW, POLAND"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrycja","family":"Major","sequence":"additional","affiliation":[{"name":"DEPARTMENT OF RHEUMATOLOGY AND IMMUNOLOGY, ANDRZEJ FRYCZ-MODRZEWSKI CRAKOW UNIVERSITY, CRAKOW, POLAND"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Go\u0142ojuch","sequence":"additional","affiliation":[{"name":"DEPARTMENT OF RHEUMATOLOGY AND IMMUNOLOGY, ANDRZEJ FRYCZ-MODRZEWSKI CRAKOW UNIVERSITY, CRAKOW, POLAND"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bogdan","family":"Batko","sequence":"additional","affiliation":[{"name":"DEPARTMENT OF RHEUMATOLOGY AND IMMUNOLOGY, J. DIETL HOSPITAL, CRACOW, POLAND"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22436","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. Engelmann C, Elsner P, Miguel D. Treatment of Pityriasis Rubra Pilaris type I: a systematic review. Eur J Dermatol. 2019;29(5):524-537. doi: 10.1684\/ejd.2019.3641.","DOI":"10.1684\/ejd.2019.3641"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. Touitou I, Galeotti C, Rossi-Semerano L et al. The expanding spectrum of rare monogenic autoinf l ammatory diseases. Orphanet J Rare Dis. 2013;8:162. doi: 10.1186\/1750-1172-8-162.","DOI":"10.1186\/1750-1172-8-162"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Moretta G, De Luca EV, Di Stefani A. Management of refractory Pityriasis Rubra Pilaris: challenges and solutions. Clin Cosmet Investig Dermatol. 2017;10:451-457. doi: 10.2147\/CCID.S124351.","DOI":"10.2147\/ccid.s124351"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Wang D, Chong VC, Chong WS, Oon HH. A Review on Pityriasis Rubra Pilaris. Am J Clin Dermatol. 2018;19(3):377-390. doi: 10.1007\/s40257-017-0338-1.","DOI":"10.1007\/s40257-017-0338-1"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. G\u00e1l B, G\u00f6bl\u00f6s A, Danis J et al. The management and genetic background of pityriasis rubra pilaris: a single-centre experience. J Eur Acad Dermatol Venereol. 2019 May;33(5):944-949. doi: 10.1111\/jdv.15455. Epub 2019 Mar 3.","DOI":"10.1111\/jdv.15455"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Ghatnekar S, Shah N, Min MS et al. Clinical features and eosinophilia in pityriasis rubra pilaris: A multicenter cohort. J Am Acad Dermatol. 2022;86(4):907-909. doi: 10.1016\/j.jaad.2021.03.043.","DOI":"10.1016\/j.jaad.2021.03.043"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. Zhou T, Al Muqrin A, Abu-Hilal M. Updates on Pityriasis Rubra Pilaris: A Scoping Review. J Cutan Med Surg. 2024;28(2):158-166. doi: 10.1177\/12034754231223159.","DOI":"10.1177\/12034754231223159"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Bar-Ilan E, Gat A, Sprecher E, Zeeli T. Paraneoplastic Pityriasis Rubra Pilaris: case report and literature review. Clin Exp Dermatol. 2017;42(1):54-57. doi: 10.1111\/ced.13009.","DOI":"10.1111\/ced.13009"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. Napolitano M, Abeni D, Didona B. Biologics for Pityriasis Rubra Pilaris treatment: A review of the literature. J Am Acad Dermatol. 2018;79(2):353-359.e11.doi: 10.1016\/j.jaad.2018.03.036.","DOI":"10.1016\/j.jaad.2018.03.036"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. Vance P, Wyles S, Alavi A. Paraneoplastic Pityriasis Rubra Pilaris Preceding Leukemia. Adv Skin Wound Care. 2022;35(6):1-4. doi: 10.1097\/01.ASW.0000826828.53117.8c.","DOI":"10.1097\/01.asw.0000826828.53117.8c"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Zhou T, Al Muqrin A, Abu-Hilal M. Updates on Pityriasis Rubra Pilaris: A Scoping Review. J Cutan Med Surg. 2024;28(2):158-166. doi: 10.1177\/12034754231223159.","DOI":"10.1177\/12034754231223159"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. Zaouak A, Chamli A, Koubaa W, Hammami H, Fenniche S. Pityriasis Rubra Pilaris. Presse Med. 2019;48(6):730-731. doi: 10.1016\/j.lpm.2019.05.009.","DOI":"10.1016\/j.lpm.2019.05.009"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Aguilar-Gamboa FR, Cubas-Alarcon D, Villegas-Chiroque M, Failoc-Rojas VE. Pityriasis Rubra Pilaris post-infection due COVID-19: case report. Colomb Med (Cali). 2021;52(1):e7014577.doi: 10.25100\/cm.v52i1.4577.","DOI":"10.25100\/cm.v52i1.4577"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Camela E, Miano C, Di Caterino P et al. Erythrodermic Pityriasis Rubra Pilaris treatment: Two case reports and literature review. Dermatol Ther. 2020;33(6):e14223. doi: 10.1111\/dth.14223.","DOI":"10.1111\/dth.14223"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. Wang D, Chong VC, Chong WS, Oon HH. A Review on Pityriasis Rubra Pilaris. Am J Clin Dermatol. 2018;19(3):377-390. doi: 10.1111\/dth.14223.","DOI":"10.1007\/s40257-017-0338-1"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16. Kromer C, Sabat R, Celis D, M\u00f6ssner R. Systemic therapies of Pityriasis Rubra Pilaris: a systematic review. J Dtsch Dermatol Ges. 2019;17(3):243-259. doi: 10.1111\/ddg.13718.","DOI":"10.1111\/ddg.13718"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"17. White KL. Pityriasis Rubra Pilaris. Dermatol Online J. 2003;9(4):6.","DOI":"10.5070\/D365618361"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18. Ghatnekar S, Shah N, Min MS et al. Clinical features and eosinophilia in Pityriasis Rubra Pilaris: A multicenter cohort. J Am Acad Dermatol. 2022 ; 86 (4): 907-909. doi: 10.1016\/j.jaad.2021.03.043.","DOI":"10.1016\/j.jaad.2021.03.043"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"19. Grif f i ths WA. Pityriasis Rubra Pilaris. Clin Exp Dermatol. 1980;5:105-112.","DOI":"10.1111\/j.1365-2230.1980.tb01676.x"},{"key":"ref19","unstructured":"20. Zito PM, Patel P, Mazzoni T. Acitretin. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan."}],"container-title":["Polski Merkuriusz Lekarski"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T07:30:32Z","timestamp":1724916632000},"score":1,"resource":{"primary":{"URL":"https:\/\/polskimerkuriuszlekarski.pl\/wp-content\/uploads\/library\/PolMerkurLek2024i3lq.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":20,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024]]},"published-print":{"date-parts":[[2024,6]]}},"URL":"https:\/\/doi.org\/10.36740\/merkur202403114","archive":["Internet Archive"],"relation":{},"ISSN":["1426-9686"],"issn-type":[{"type":"print","value":"1426-9686"}],"subject":[],"published":{"date-parts":[[2024]]}}}